✦ LIBER ✦

382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study

✍ Scribed by S.C. Pacey; M.J. Ratain; P.O. O'Dwyer; H. Xiong; A. Patnaik; T. Eisen; D. Eaton; R.J. Lee; B. Schwartz; I. Judson

Book ID: 118621564
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 291 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)80389-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

381 A phase I study of BAY 43-90006, a n

381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors

✍ A. Awada; A. Hendlisz; T. Gil; B. Schwartz; S. Bartholomeus; E. Brendel; D. de V 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 147 KB

A clinical phase I and biomarker study o

A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 281 KB

Final results of a phase I study of the

Final results of a phase I study of the Raf-1 kinase inhibitor bay 43-9006 in patients with advanced refractory solid tumours

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Phase I Clinical and Pharmacokinetic Stu

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

✍ Strumberg, D. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 207 KB

Phase I Clinical and Pharmacokinetic Stu

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

✍ Strumberg, D. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 207 KB

## Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.